Literature DB >> 8784793

Luteinizing hormone and human chorionic gonadotropin fragment the migrating myoelectric complex in rat small intestine.

T E Ducker1, J W Boss, S A Altug, H Mehrabian, D R Dekeratry, M H Clench, J R Mathias.   

Abstract

We hypothesized that sex hormones may affect motility disorders because these diseases occur more often in women than in men, and symptoms often occur or worsen after ovulation. Luteinizing hormone (LH) is predominantly secreted by the anterior pituitary midway through the menstrual cycle; it results in the development of the corpus luteum. LH levels also increase after bilateral gonadectomy. LH and human chorionic gonadotropin (hCG) bind to the same receptor, but rats lack hCG. To assess how LH and hCG influence myoelectric activity of the small intestine and to test the specificity of the LH receptor, we implanted electrodes on the jejunum of female rats. LH (0.1 or 0.5 NIH units) was administered intraperitoneally to intact and gonadectomized rats and 0.5 NIH units to rats that had been both hypophysectomized and gonadectomized; intact animals were treated with 100 units USP of hCG. Recordings were made with the rats in fasted and in fed states, and their intestinal motility was analysed. The most striking effects of LH, hypophysectomy, and hCG were the same: phase III of the migrating myoelectric complex was markedly fragmented and its duration lengthened (P < 0.0001). Gonadectomy alone and gonadectomy with hypophysectomy also increased fragmentation and phase III duration (P < 0.01 or better). LH receptors respond similarly to LH and hCG, and both hormones alter myoelectric activity of the rat small intestine in comparable ways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8784793     DOI: 10.1111/j.1365-2982.1996.tb00249.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  8 in total

1.  Antibodies against gonadotropin-releasing hormone (GnRH) and destruction of enteric neurons in 3 patients suffering from gastrointestinal dysfunction.

Authors:  Bodil Ohlsson; Eva Ekblad; Béla Veress; Agneta Montgomery; Sabina Janciauskiene
Journal:  BMC Gastroenterol       Date:  2010-05-20       Impact factor: 3.067

2.  Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study.

Authors:  J R Mathias; M H Clench; T L Abell; K L Koch; G Lehman; M Robinson; R Rothstein; W J Snape
Journal:  Dig Dis Sci       Date:  1998-06       Impact factor: 3.199

3.  New insights into the understanding of gastrointestinal dysmotility.

Authors:  Bodil Ohlsson; Sabina Janciauskiene
Journal:  Drug Target Insights       Date:  2007-09-25

4.  The Expression of Serum Antibodies Against Gonadotropin-releasing Hormone (GnRH1), Progonadoliberin-2, Luteinizing Hormone (LH), and Related Receptors in Patients with Gastrointestinal Dysfunction or Diabetes Mellitus.

Authors:  Bodil Roth; Kerstin Berntorp; Bodil Ohlsson
Journal:  Drug Target Insights       Date:  2014-11-10

Review 5.  Gonadotropin-Releasing Hormone and Its Role in the Enteric Nervous System.

Authors:  Bodil Ohlsson
Journal:  Front Endocrinol (Lausanne)       Date:  2017-06-07       Impact factor: 5.555

6.  Autoantibodies and gastrointestinal symptoms in infertile women in relation to in vitro fertilization.

Authors:  Oskar Hammar; Bodil Roth; Mariette Bengtsson; Thomas Mandl; Bodil Ohlsson
Journal:  BMC Pregnancy Childbirth       Date:  2013-11-05       Impact factor: 3.007

7.  Long‑term follow‑up of buserelin‑induced enteric neuropathy in rats.

Authors:  Anette Jönsson; Elin Sand; Eva Ekblad; Bodil Ohlsson
Journal:  Mol Med Rep       Date:  2016-03-03       Impact factor: 2.952

8.  Expression of Luteinizing Hormone Receptor in the Gastrointestinal Tract in Patients with and without Dysmotility.

Authors:  Oskar Hammar; Béla Veress; Agneta Montgomery; Bodil Ohlsson
Journal:  Drug Target Insights       Date:  2012-04-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.